All In Biotech

Free tool

FAERS Monitor: Dayvigo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 212028 or its brand name (Dayvigo, Lemborexant). Reports on generic versions are filed under their own applications.

Reports

2,946

Serious

2,287

78% of reports

Hospitalization

1,317

Death reported

370

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective332
  • off label use215
  • suicide attempt175
  • condition aggravated157
  • suicidal ideation156
  • somnolence149
  • fall111
  • nausea104
  • dizziness97
  • headache97
  • insomnia94
  • adverse drug reaction92
  • pyrexia91
  • sleep paralysis88
  • malaise86

Reports by year received

View as table
YearReports
20151
20181
20192
2020199
2021320
2022376
2023420
2024554
2025604
2026469

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,213 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
sleep paralysisSignal88455.3368.237,081
suicide attemptSignal17520.717.93,255
suicidal ideationSignal15612.210.51,595
adverse drug reactionSignal927.36.0497
somnolenceSignal1495.34.5518
condition aggravatedSignal1573.73.2309
insomniaSignal942.52.186
fallSignal1112.42.089
pyrexia911.91.537
drug ineffective3321.81.6125
off label use2151.81.572
malaise861.41.110
dizziness971.41.110
headache971.10.91
nausea1040.90.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.